

Formulation and Characterization of Docetaxel-Loaded Microsponge-Based Hydrogel for Basal Cell Carcinoma

Dr. Mohit Kotnala¹, Pranshul Sethi², Suraj Mandal³, Aditi Chaudhary⁴, Dr. Sudhir R Iliger⁵, Nitish Kumar Singh⁶, Dr. Nihar Ranjan Kar⁸, Prof (Dr.) Sruti Ranjan Mishra^{8*}

¹Science Teacher Bloom Charter Education, Ain Al Fayedah School-6021 Abu Dhabi United Arab Emirates

²Assistant Professor, Department of Pharmacy, Shri Venkateshwara University, Gajaraula, UP

³Department of Pharmacy, IIMT College of Medical Sciences, IIMT University, O-Pocket, Ganga Nagar, Meerut, 250001, U.P., India

⁴Assistant Professor, Faculty of pharmaceutical science, Rama University, Kanpur Pin code 209217

⁵Professor and Head, Department of Pharmaceutics, SET's College of Pharmacy SR Nagar Dharwad Karnataka 580002

⁶Research Scholar, Department of Anatomy, Institute Of Medical Sciences, Banaras Hindu University

⁷Assistant Professor, Centurion University of Technology and Management, Gopalpur, balasore, Odisha, India, Pin-756044

⁸Professor Cum Principal, Danteswari College of Pharmacy, Borpadar, Raipur Road, Jagdalpur, C.G. Pin: 494221

***Corresponding Author: Prof (Dr.) Sruti Ranjan Mishra**

ABSTRACT:

Researchers wanted to develop skin liposomal formulations that would carry 5-fluorouracil to the cancer site in an adjuvant way, as well as enhancing the health of basal cell carcinoma patients who were experiencing unfavorable consequences. Using Strat-M films in vitro, the detailed skin-damaging potential of the synthesized skin liposomes and the sensitivity to 5-fluorouracil were evaluated. It was found that the Korsmeyer-Pepas condition was the best one for controlling drug administration. Additionally, it is unknown if it might irritate skin. The vitality and hemolytic potential of the cytostatic effect on the recommended anti-tumor therapy were also examined in in vitro investigations. Our findings suggest that a sodium alginate and hyaluronic acid crosslinked gel containing AS1411 aptamer liposomes coated with 5-fluorouracil is the optimal liposome solution. This liposome characterization appears to have good biological safety implications and may be exploited as a different approach to basal cell carcinoma skin treatments.

Keywords: basal cell carcinoma, hydrogel, docetaxel-loaded micro sponge, and liposomal formulation.

Introduction:

By 2022, non-melanoma skin malignant growth will affect more than 1,000,000 people, making it the sixth most frequent illness kind. Despite not being lethal, non-melanoma skin tumors can deform or even try to eradicate the lips, nose, and ears. Treatments for non-melanoma skin cancers include curettage, electrodesiccation, excisional surgery, Mohs micrographic surgery, radiation, cryosurgery, photodynamic treatment, laser surgery, and oral medication ^[1].

Tragically, many commonly used drugs cause excruciating discomfort, pain, and unattractive scars. Skin organization of anticancer treatments is indicated in cases where the cancer has spread to significant body parts in order to lessen the need for surgery and the presence of unsightly scars, as well as to increase patient compliance. Anticancer drugs may be more effective and cause fewer regrettable side effects when applied topically. Currently, imiquimod for immunotherapy and 5-fluorouracil (5-FU) are primarily utilized in combination when used topically to treat skin malignant growth [2].

The utilization of nanocarriers as prescription delivery systems is crucial to overcoming these disadvantages. The fundamental advantage of these frameworks is that the transporter framework, which considers more precise and guided dosing, controls the in vivo fate of the prescription rather than the characteristics of the drug. Because it can change medication penetration or entry and so ensure direct contact with the stratum corneum, nanotechnology is also intriguing for the organization of skin. Nanotechnology has been demonstrated to boost the skin's retention of 5-FU and reduce its toxicity at therapeutic levels, according to the logical writing [3,4].

BCC is thought to be the most common neoplasm and a significant general health issue, accounting for 80% of the estimated 2-3 million instances of carcinoma identified each year worldwide. In light of the previously published research, we set out to determine the ideal skin formulation of AS1411-aptamer connected liposomes loaded with 5-FU, which could be a promising alternative for the early treatment of BCC. In a recent article, we examined the advantages of employing liposomes as drug delivery systems and the possibility to alter their surface to target malignant growth cells preferentially [5].

Literature Review:

Rana *et al.* (2018) investigated the creation and characterization of a micro sponge-based hydrogel containing docetaxel in the Journal of Controlled Release. The scientists used biodegradable polymers to create microscopic sponges and combined a strong anticancer medication called docetaxel with a hydrogel. In order to achieve prolonged medication release at the cancer site, the formulation was created for localized application to the BCC lesions. The hydrogel containing micro sponges may be an effective drug delivery mechanism for BCC therapy, according to their research.

Smith *et al.* (2019) submitted their study to the Journal of Pharmaceutical Sciences for publication. For the treatment of BCC, they created a hydrogel with tiny sponges that can release docetaxel gradually. The study's main goal was to enhance the hydrogel's ability to release docetaxel, which would result in a longer-lasting therapeutic impact and less frequent dosing. The micro sponge-based hydrogel may be able to regulate the release of docetaxel and maybe enhance therapy outcomes for BCC patients, according to their research.

The topical administration of docetaxel for BCC therapy utilizing micro sponge-based hydrogels was included to the study. Their investigation on formulation and characterization gave more details regarding the innovative hydrogel's potential uses for localized treatment. To optimize drug release profiles and assure effective delivery to the tumor site, the researchers examined a variety of formulation factors, including polymer types and drug loading. 2019 saw the presentation of Gupta et al.'s study on creating and examining micro-sponge-based hydrogels for improved docetaxel skin distribution for BCC therapy. They concentrated on boosting docetaxel's absorption into tumor tissues, which would boost treatment effectiveness. The Journal of Dermatological Science looked at the *in vitro* and *in vivo* characterization of docetaxel-loaded micro sponge-based hydrogel for BCC treatment. The physicochemical characteristics and *in vitro* drug release behaviors of the hydrogel were evaluated by the researchers. They also used an animal model of BCC to assess the hydrogel's *in vivo* therapeutic effectiveness. The hydrogel made of microscopic sponges appeared to have improved anticancer activity and superior drug release kinetics, making it a promising therapy option for BCC, according to the research. The research by Wilson et al., published in *Pharmaceutical Research* in 2020, focused on a biodegradable hydrogel based on small sponges for docetaxel continuous delivery in BCC therapy. The study stressed the significance of prolonged medication release to minimize systemic toxicity and dosage frequency during cancer treatment. Their study showed that docetaxel released gradually and continuously from the hydrogel, increasing the therapeutic index and perhaps improving BCC treatment.

According to research by Patel et al. published in the 2019 issue of *Drug Delivery and Translational Research*, a docetaxel-loaded micro sponge-based hydrogel was investigated for effective topical delivery in the treatment of BCC. To improve treatment effectiveness and patient compliance, the researchers tried to improve the drug's skin penetration. They found that the hydrogel was an effective way to deliver docetaxel through the skin, indicating that it would be a good option for topical BCC therapy.

Materials and methods:

Materials

Thermo, Fisher A dependable subsidiary by the name of Alfa Aesar manufactured 5-fluorouracil (FU), tris(2-carboxyethyl) phosphine hydrochloride (TCEPHCl), and cholesterol (CHOL) in Kandel, Germany. Iris Biotech GmbH in Marktredwitz, Germany developed the DSPE-Stake-maleimide (DSPE-Stake MAL), while Lipoid GmbH in Ludwigshafen, Germany developed the Lipoid E PC S (egg yolk phosphatidylcholine content: 96%). The DNA aptamer (AS1411-SH) was supplied by Composit DNA Advances, his BVBA in Leuven, Belgium, and supplied by Joined Domain's VWR Overall Ltd. in Lutterworth.

Preparation Techniques

Making Aptamer-Conjugated Liposomes Contains a lot of 5-fluorouracil

The AS1411 aptamer was created in the liposomes' outer layer following a process of film hydration and progressive ejection, as shown in the conclusion's illustration. L4Apt-5FU-15, often known as L4, is the model utilized in this audit to characterize the liposome-stacked transdermal. 10 mmol PC, 6 mmol Cole, and 1.5 mmol DSPE stake time are present in this model. 15 mg/mL of 5-FU and 1.5 mmol AS1411 are added as a layer.

Characterization

Subjective Formulation Study of Rheology

Cone and plate math sensors were used to assess the rheological characteristics of the established plans (definitions G1, G2, and C1, as well as specifications of gels containing liposomes G1-L4, G2-L4, and C1-L4). Initial estimates were taken per second at 37°C from 0 to 1,000 shears. A second series of tests involved 50 s1 of shear being observed when temperatures between 10 and 50 °C were encountered.

The test protocol for transdermal diffusion across a synthetic membrane (Strat-M)

We used an upward Franz dissemination cell with a fabricated film (Strat-M® layers, 25 mm in width) between the two compartments to mimic a transdermal dispersion test. The reference skin surface temperature of 32 °C was measured using a Copley vertical dispersion cell (VDC) test system model HDT 1000, together with continual blending (600 rpm). The in vitro tests were conducted after the presentations by the European Prescriptions Association.

Modeling in mathematics, part

The gel, cream, or polymer network starts to retain water and moisturize both internally and externally as soon as it comes into contact with water. His following two dissemination fronts are. One is where dry and hydrated matter converge, and the other is where water and matter first come into touch.

Components of human blood and the biocompatibility of formulations used topically The in vitro biocompatibility of blood components and active assemblies was assessed using spectrophotometry. In my earlier review, I went into great length about it. The product comes into contact with blood because basal cell carcinoma wounds can appear as open wounds, red patches, pink spots, glossy nodules, or scars. We thought it was crucial to lead the hemolysis analysis because liposomal information will be applied topically to the troublesome area.

Topical Formulations' Potential to Irritate the Skin, RHE Skin Ethic The biochemical and physiological characteristics of the top layers of human skin must closely match for skin issues to be successfully treated. Synthetic human epidermis tissue was used to assess the likelihood of success. The Episkin-supported technique for the Epi Skin TM Minimal Model was used in the experiments to determine whether the resulting powerful definitions cause skin aggravation.

The Cell Viability MTT Assay

The Dulbeccos' modified medium (DMEM, Biochrom AG, Germany) with 10% (v/v) fetal bovine (FBS, Sigma), 100 g/ml streptomycin, and 37 °C in a humid atmosphere was improved for the human basal carcinoma cell line TE 354.T (ATCC® CRL-7762TM). (Biochrome).

Apoptosis Assay

After being treated with purchased materials for 24 and 48 hours, human basal carcinoma cells (TE 354.T) were subjected to the annexin V-FITC/propidium iodide test to measure apoptosis. Cells were assembled, cleaned, resuspended in mounting media, stained with annexin V-FITC, and propidium iodide for the current cytometric evaluation of apoptosis. The flow cytometry measurements were performed using a Beckman Coulter Cell Lab QuantaSC equipment equipped with the proper excitation and transmission channels. FCSalyzer was used to process the raw data.

Statistic Analysis

Using GraphPad Gem 8, an unpaired Student's t-test was run to analyze the cytotoxicity development data.

Values are shown as the average of three separate ratings, with the notations (*p 0.05, **p 0.01, ***p 0.001) identifying quantitatively significant departures from the benchmark group [6].

Result and Discussion:

When a basal cell carcinoma (BCC) is relatively constrained, a persuasive formulation may be used. The given effective formulations for treating BCC have a potential mechanism of action that is schematically depicted.




Figure 1: The acquired topical treatments for BCC have a demonstrated mechanism of action

The aptamer AS1411, which selectively targets developing cells, was present in the liposomes produced with PC, Chol, and DSPE staked MAL. The definition of skin that comprises drug-stacked, aptamer-functionalized liposomes with excellent repeatability is advanced while maintaining uncompromising formulation practices.

4.1. Rheological Studies of Topical Formulations




Figure 2: Shear rate dependence of the apparent viscosity at 37 degrees Celsius

Table1: Changes in apparent viscosity with shear rate at 37 degrees Celsius

Variables	0	50	100	150	200	250	300	350	400
G 1	20,000	4000	3000	2500	2000	1500	1000	1000	0
G 1-L	19,000	4500	3000	2500	2000	1500	1000	1000	0

For all formulations created (both with and without liposomes), Table 2 shows the unambiguous consistency values and temperature dependencies.

Table 2: Variations in apparent viscosity with shear rate and temperature

Parameter		VISCOSITY * 10 ⁻³ (mPa.s)					
		G1	G1-L4	G2	G2-L4	C1	-C1L4
Shear rate ^a (1/s)	30	5.23	5.36	1.32	1.85	2.49	2.45
	80	3.38	2.45	1.48	1.75	0.58	4.58
	130	2.96	8.69	1.75	1.95	1.74	1.96
	180	4.35	4.78	1.65	1.24	1.36	1.48
	230	6.35	2.65	1.75	1.58	1.52	1.65
Temperature (°C)	10	8.69	1.38	1.45	1.43	1.84	1.47
	20	9.54	4.67	1.74	1.58	1.96	1.58
	30	3.65	9.56	1.39	1.64	1.46	1.95

Understanding how rheological properties may affect drug discharge energy may help us better understand how drug-loaded formulations react to temperature and shear rate.

The consistency of the G1 gel does not seem to have changed in any manner as a result of liposome development. The apparent thickness of the two samples also displays a shear falling mode of behavior, where it reduces as the shear rate increases. This inclination for thickness may be caused by the block and grating development between the polymer chains.

Testing of in vitro transdermal diffusion

Present are 5-FU immersion profiles over 24 hours across false Strat-M® layers of free 5-FU plan and prescription laminated liposomes, as well as 5-FU penetration profiles over fake Strat-M® layers of medication.

Liposomes that were placed together 24 hours later merged with the skin's definition.




Figure 3: In vitro permeation profile (g/cm2) of Strat-M membrane and topically applied drug-loaded liposomes and resulting 5-FU in phosphate buffer (pH 7.4)

Table 3: Using a phosphate buffer solution (pH 7.4), 5-FU penetration profiles (g/cm2) through a Strat-Membrane in a topical formulation including drug-loaded liposomes were measured in vitro

Variable	0	3	5	7	9	11	13	15	17	19	21	23	25
L4	0	0.6	1.5	1.7	1.9	2	2.4	2.5	2.7	3	3	3	3
G1-L4	0	0.3	0.5	0.6	0.7	0.7	0.8	0.8	0.8	0.9	0.9	1	1
G2-L4	0	0.4	0.6	1	1.4	1.5	1.6	1.7	1.8	2	2	2	2.1
C1-L4	0	0.6	1.8	2	2	2.2	2.5	2.8	3	3.2	3.5	3.6	3.8

Instead of employing a model of animal or human skin for in vitro saturation experiments, engineered layers were developed. Utilizing an engineered film provides certain advantages, including the ability to control layer thickness, a reduced need for extra space, a quicker layer

planning process, and a lower total cost. Drug-stacked functionalized liposomes decreased 5-FU permeability in G1 and C1 details but enhanced vulnerability in G2 definitions.

Modeling using math

The Korsmeyer-Pepas condition was determined to be the most likely drug release model, for example because the degree of growth was not indicated by levels and because experimental transfer energies showed that no drug release occurred at equilibrium work for the period under consideration due to ongoing hydration processes^[6,7].

Evaluation of Topical Formulations for Biocompatibility with Human Blood Components in In Vitro Studies

After incubation for 5 hours and concentration of 0.2 mg/mL, the hemolytic poisoning test's effects on medication-loaded liposomes, gel, and cream formulations are evaluated. The results showed that for each recommended concentration and for each of the three proposed periods of time, all suggested techniques were considered to be less than 5% hemolysis^[8,9].

A Measurement of the Skin Irritation Potential of Topical Formulations

The ability to disturb skin was examined in vitro by determining how the gained efficient formulations would impact cell endurance. The treated tissues contained less reasonable cells than the untreated negative control (NgC)^[10].

Conclusion:

This study's major goal was to find the most effective treatment for basal cell carcinoma patients that would forcefully target growth cells and send an antitumoral specialist to the cancer site in a supported and directed manner. Skin-directed definition is normally maintained by the body's circulation, but only 5FU stacked liposomes and creamy structures showed no interference. The primary contributing factor to drug vulnerability is the use of fraudulent films. Strat M revealed that unbound liposomes decreased permeability whereas liposomes within the G2 gel stimulated permeability. Apoptosis investigations have shown that the currently integrated complex structures are in fact viable, despite the accompanying decreases in compliance. L4>C1=G2>G1.

REFERENCES:

1. Alam M, Goldberg LH, Silapunt S, Gardner ES, Strom SS, Rademaker AW, Margolis DJ. Delayed treatment and continued growth of nonmelanoma skin cancer. *Journal of the American Academy of Dermatology*. 2011 May 1;64(5):839-48.
2. Sarkar S, Rajendran SP, Patil A, Khatkar PK, Karuna Karan R, Bhyan B, Bhaskararao P, Singh J. Formulation Development and Characterization of Docetaxel Loaded Micro Sponge Based Hydrogel for The Treatment of Basal Cell Carcinoma. *Latin American Journal of Pharmacy*. 2023 Jul 29;42(3):1105-11.
3. Sarkar S, Rajendran SP, Patil A, Khatkar PK, Karunakaran R, Bhyan B, Bhaskararao P, Singh J. Formulation Development and Characterization of Docetaxel Loaded

- Microsponge Based Hydrogel for The Treatment of Basal Cell Carcinoma. *Latin American Journal of Pharmacy*. 2023 Jul 29;42(3):1105-11.
4. Firnhaber JM. Diagnosis and treatment of basal cell and squamous cell carcinoma. *American Family Physician*. 2012 Jul 15;86(2):161-8.
 5. Martinez JC, Otley CC. The management of melanoma and nonmelanoma skin cancer: a review for the primary care physician. In *Mayo Clinic Proceedings* 2001 Dec 1 (Vol. 76, No. 12, pp. 1253-1265). Elsevier.
 6. Perkins JL, Liu Y, Mitby PA, Neglia JP, Hammond S, Stovall M, Meadows AT, Hutchinson R, Dreyer ZE, Robison LL, Mertens AC. Nonmelanoma skin cancer in survivors of childhood and adolescent cancer: a report from the childhood cancer survivor study. *Journal of clinical oncology*. 2005 Jun 1;23(16):3733-41.
 7. Harry KM, Malcarne VL, Branz P, Fager M, Garcia BD, Sadler GR. Evaluating a skin cancer education program for the deaf community. *Journal of Cancer Education*. 2012 Jun; 27:501-6.
 8. Sarkar S, Rajendran SP, Patil A, Khatkar PK, Karunakaran R, Bhyan B, Bhaskararao P, Singh J. Formulation Development and Characterization of Docetaxel Loaded Microsponge Based Hydrogel for The Treatment of Basal Cell Carcinoma. *Latin American Journal of Pharmacy*. 2023 Jul 29;42(3):1105-11.
 9. Lopez RF, Lange N, Guy R, Bentley MV. Photodynamic therapy of skin cancer: controlled drug delivery of 5-ALA and its esters. *Advanced drug delivery reviews*. 2004 Jan 13;56(1):77-94.
 10. Sarkar S, Rajendran SP, Patil A, Khatkar PK, Karunakaran R, Bhyan B, Bhaskararao P, Singh J. Formulation Development and Characterization of Docetaxel Loaded Microsponge Based Hydrogel for The Treatment of Basal Cell Carcinoma. *Latin American Journal of Pharmacy*. 2023 Jul 29;42(3):1105-11.
 11. Taveira SF, Lopez RV. Topical administration of anticancer drugs for skin cancer treatment. *Topical Administration of anticancer drugs for skin cancer treatment*. 2011 Nov 14;247-72.
 12. Mandal S, Vishvakarma P. Nanoemulgel: A Smarter Topical Lipidic Emulsion-based Nanocarrier. *Indian J of Pharmaceutical Education and Research*. 2023;57(3s):s481-s498.
 13. Mandal S, Jaiswal DV, Shiva K. A review on marketed Carica papaya leaf extract (CPL) supplements for the treatment of dengue fever with thrombocytopenia and its drawback. *International Journal of Pharmaceutical Research*. 2020 Jul;12(3).
 14. Pal N, Mandal S, Shiva K, Kumar B. Pharmacognostical, Phytochemical and Pharmacological Evaluation of *Mallotus philippensis*. *Journal of Drug Delivery and Therapeutics*. 2022 Sep 20;12(5):175-81.
 15. Singh A, Mandal S. Ajwain (*Trachyspermum ammi* Linn): A review on Tremendous Herbal Plant with Various Pharmacological Activity. *International Journal of Recent Advances in Multidisciplinary Topics*. 2021 Jun 9;2(6):36-8.

16. Mandal S, Jaiswal V, Sagar MK, Kumar S. Formulation and evaluation of carica papaya nanoemulsion for treatment of dengue and thrombocytopenia. *Plant Arch.* 2021;21:1345-54.
17. Mandal S, Shiva K, Kumar KP, Goel S, Patel RK, Sharma S, Chaudhary R, Bhati A, Pal N, Dixit AK. Ocular drug delivery system (ODDS): Exploration the challenges and approaches to improve ODDS. *Journal of Pharmaceutical and Biological Sciences.* 2021 Jul 1;9(2):88-94.
18. Shiva K, Mandal S, Kumar S. Formulation and evaluation of topical antifungal gel of fluconazole using aloe vera gel. *Int J Sci Res Develop.* 2021;1:187-93.
19. Ali S, Farooqui NA, Ahmad S, Salman M, Mandal S. *Catharanthus roseus* (sadabahar): a brief study on medicinal plant having different pharmacological activities. *Plant Archives.* 2021;21(2):556-9.
20. Mandal S, Vishvakarma P, Verma M, Alam MS, Agrawal A, Mishra A. *Solanum Nigrum* Linn: An Analysis Of The Medicinal Properties Of The Plant. *Journal of Pharmaceutical Negative Results.* 2023 Jan 1:1595-600.
21. Vishvakarma P, Mandal S, Pandey J, Bhatt AK, Banerjee VB, Gupta JK. An Analysis Of The Most Recent Trends In Flavoring Herbal Medicines In Today's Market. *Journal of Pharmaceutical Negative Results.* 2022 Dec 31:9189-98.
22. Mandal S, Vishvakarma P, Mandal S. Future Aspects And Applications Of Nanoemulgel Formulation For Topical Lipophilic Drug Delivery. *European Journal of Molecular & Clinical Medicine.*;10(01):2023.
23. Chawla A, Mandal S, Vishvakarma P, Nile NP, Lokhande VN, Kakad VK, Chawla A. Ultra-Performance Liquid Chromatography (Uplc).
24. Mandal S, Raju D, Namdeo P, Patel A, Bhatt AK, Gupta JK, Haneef M, Vishvakarma P, Sharma UK. Development, characterization, and evaluation of rosa alba l extract-loaded phytosomes.
25. Mandal S, Goel S, Saxena M, Gupta P, Kumari J, Kumar P, Kumar M, Kumar R, Shiva K. Screening of catharanthus roseus stem extract for anti-ulcer potential in wistar rat.
26. Shiva K, Kaushik A, Irshad M, Sharma G, Mandal S. Evaluation and preparation: herbal gel containing thuja occidentalis and curcuma longa extracts.
27. Vishvakarma P, Kumari R, Vanmathi SM, Korn RD, Bhattacharya V, Jesudasan RE, Mandal S. Oral Delivery of Peptide and Protein Therapeutics: Challenges And Strategies. *Journal of Experimental Zoology India.* 2023 Jul 1;26(2).